PDX Finder: A Portal for Patient-Derived tumor Xenograft Model Discovery

Nathalie Conte, Jeremy Mason, Csaba Halmagyi, Steven B Neuhauser, Abayomi Mosaku, Dale A Begley, Debra M Krupke, Helen Parkinson, Terrence Meehan, Carol J Bult

Preprint posted on April 05, 2018

Article now published in Nucleic Acids Research at

An open information resource for patient-derived tumor models: PDX Finder as a searchable portal to improve visibility, transparency and communication in cutting-edge cancer research.

Selected by Carmen Adriaens


In the past 15 years, tens of laboratories all over the world have implemented patient-derived tumor xenograft (PDX) models as a powerful tool to study cancer. The principle is simple: upon biopsy in the clinic, a piece or a suspension of the resected tumorous tissue is engrafted either orthotopically or subcutaneously in an immunocompromised mouse. If the graft is successful, the grown tumor can be re-transplanted (expanded) into another set of mice (2nd generation) and so on, until several mice bear the same parent tumor and can be used for experiments. Over generations of host mice, the human tumor stroma is usually replaced by mouse stroma, but the cancerous tissue retains its principal molecular and histological characteristics.

PDX models have several advantages over in vitro– or cell line graft- based techniques. For instance, they retain well the cellular heterogeneity found in the original tumors and they usually respond to a treatment in a manner similar to the donor. They can even be predictive of resistance development or response rate. Moreover, as opposed to genetically engineered mouse models (GEMMs), the cells are of human origin, and data generated for the models is directly relevant to the study of human cancer biology.

PDX models are used for several cancer-related applications. For instance, the engraftment rate and success of a tumor can be examined diagnostically to determine stage and aggressiveness. They are employed to resolve important biological questions such as what the tumor heterogeneity is, whether a cell-of-origin exists, or if certain tumor cells are intrinsically resistant to therapy. Recently, the field has imagined a more clinically relevant application: although expensive and not devoid of risk (and if anything, still in a very controversial light), PDX models could be used as “avatars” for cancer patients. In such a scenario, several drug combinations and treatment courses can be tested and characterized before an actual therapy scheme is established in the clinic.


The problem


Alone, we can do so little; together, we can do so much.” — Helen Keller


Although many labs have developed PDX models, the techniques to do so are not standardized and the reporting and availability of data, especially, are limited and scattered, or very heterogeneous among different groups. In a community effort, several world-wide consortia recently established PDX-MI, a Minimal Information set of guidelines that recommends PDX users to report “essential” and “desirable” data modules when new models or research is published (Meehan, Conte et al. Cancer Research, 2017). Since the use of PDX is rapidly expanding, there is a pressing need for a centralized database containing the available models and their minimal information. A such, they can be shared globally to prevent redundant studies and the perfect PDX and associated data can be easily found for the specific research question asked.


The preprint

In this preprint, Conte et al. present PDX Finder (, an online database aiming to solve the decentralization of available models and the information about them. For now, seven PDX centers (one in Italy, six in the US) have joined the database. The authors invite all other centers from around the world to participate.

PDX finder provides a searchable platform for PDX models of different cancer types, and searches can be narrowed to the geographical location of the model, the anatomical system, collection site, molecular characteristics, type of host and patient, mouse generation etc. It will be updated with clinically and biologically relevant information, where available, and aims to improve the visibility of cancer models for future studies.


My opinion

Overall, I think this preprint is a clear and concise description of the website and serves its citation and dissemination purposes well. Importantly, I believe this manuscript is a worthy attempt to address a recurrent issue in modern science: the lack of transparency, standardization, data availability, and mobility of reagents and skills.

This preprint and the PDX Finder website is a small but important step forward by aiming to centralize the information. It may help to increase the visibility of available models and stimulate communication between biologists, clinicians, and informaticians. Hopefully, the platform will encourage exchange among different centers and laboratories, which will be especially valuable when done within the framework of the PDX-MI. Furthermore, the use of animal models for research and clinical purpose is obviously not without controversy. This database may hence contribute to the three R’s – Replace, Reduce, Refine. A central platform can help to avoid duplicate models for fundamental research, and in contrast, may reveal gaps in molecular subtypes for individual tumor type PDX models.

In conclusion, I believe that, although as with all animal models their use needs reasonable caution, overall PDX models are an excellent and robust tool to study cancer. In past years they appear to have taken center stage successfully and seem ready to revolutionize cancer research. I like to think we all strive towards the same objective of understanding and trying to cure cancer, and we will need to bundle our efforts to succeed. Ultimately, PDX Finder may help to achieve that goal in an effective and transparent manner.



Tags: database, disease model, issues in science, patient derived tumor xenograft, worldwide consortia

Posted on: 20th April 2018

Read preprint (No Ratings Yet)

Have your say

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Sign up to customise the site to your preferences and to receive alerts

Register here

Also in the cell biology category:


The advances in fibroblast biology preList explores the recent discoveries and preprints of the fibroblast world. Get ready to immerse yourself with this list created for fibroblasts aficionados and lovers, and beyond. Here, my goal is to include preprints of fibroblast biology, heterogeneity, fate, extracellular matrix, behavior, topography, single-cell atlases, spatial transcriptomics, and their matrix!


List by Osvaldo Contreras

EMBL Synthetic Morphogenesis: From Gene Circuits to Tissue Architecture (2021)

A list of preprints mentioned at the #EESmorphoG virtual meeting in 2021.


List by Alex Eve

FENS 2020

A collection of preprints presented during the virtual meeting of the Federation of European Neuroscience Societies (FENS) in 2020


List by Ana Dorrego-Rivas

Planar Cell Polarity – PCP

This preList contains preprints about the latest findings on Planar Cell Polarity (PCP) in various model organisms at the molecular, cellular and tissue levels.


List by Ana Dorrego-Rivas

BioMalPar XVI: Biology and Pathology of the Malaria Parasite

[under construction] Preprints presented at the (fully virtual) EMBL BioMalPar XVI, 17-18 May 2020 #emblmalaria


List by Dey Lab, Samantha Seah


Cell Polarity

Recent research from the field of cell polarity is summarized in this list of preprints. It comprises of studies focusing on various forms of cell polarity ranging from epithelial polarity, planar cell polarity to front-to-rear polarity.


List by Yamini Ravichandran

TAGC 2020

Preprints recently presented at the virtual Allied Genetics Conference, April 22-26, 2020. #TAGC20


List by Maiko Kitaoka et al.

3D Gastruloids

A curated list of preprints related to Gastruloids (in vitro models of early development obtained by 3D aggregation of embryonic cells). Updated until July 2021.


List by Paul Gerald L. Sanchez and Stefano Vianello

ECFG15 – Fungal biology

Preprints presented at 15th European Conference on Fungal Genetics 17-20 February 2020 Rome


List by Hiral Shah

ASCB EMBO Annual Meeting 2019

A collection of preprints presented at the 2019 ASCB EMBO Meeting in Washington, DC (December 7-11)


List by Madhuja Samaddar et al.

EMBL Seeing is Believing – Imaging the Molecular Processes of Life

Preprints discussed at the 2019 edition of Seeing is Believing, at EMBL Heidelberg from the 9th-12th October 2019


List by Dey Lab


Preprints on autophagy and lysosomal degradation and its role in neurodegeneration and disease. Includes molecular mechanisms, upstream signalling and regulation as well as studies on pharmaceutical interventions to upregulate the process.


List by Sandra Malmgren Hill

Lung Disease and Regeneration

This preprint list compiles highlights from the field of lung biology.


List by Rob Hynds

Cellular metabolism

A curated list of preprints related to cellular metabolism at Biorxiv by Pablo Ranea Robles from the Prelights community. Special interest on lipid metabolism, peroxisomes and mitochondria.


List by Pablo Ranea Robles

BSCB/BSDB Annual Meeting 2019

Preprints presented at the BSCB/BSDB Annual Meeting 2019


List by Dey Lab


This list of preprints is focused on work expanding our knowledge on mitochondria in any organism, tissue or cell type, from the normal biology to the pathology.


List by Sandra Franco Iborra

ASCB/EMBO Annual Meeting 2018

This list relates to preprints that were discussed at the recent ASCB conference.


List by Dey Lab, Amanda Haage